Geron stock is seeing a dramatic pullback following the company's fourth-quarter report. Geron's earnings in Q4 fell short of Wall Street's expectations, and management had worrying guidance for ...

Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Geron is a commercial-stage biopharmaceutical company that focuses on the development of ...

Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly ...